On October 13, 2015 Varian Medical Systems, Inc., (NYSE: VAR) reported plans to offer cancer centers a powerful new interactive software engine that will enable radiation oncologists to quickly create, review and optimize radiotherapy and radiosurgery dose prescriptions for their patients (Press release, InfiMed, OCT 13, 2015, View Source [SID:1234507705]). The company has acquired HyperDrive software technology that will be further developed to both improve the quality of prescriptions and accelerate the treatment planning process. Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
HyperDrive was developed by Karl Otto, adjunct professor of medical physics at the University of British Columbia, who was also instrumental in the development of Varian’s RapidArc radiotherapy, which expedited delivery of high-precision intensity-modulated radiation therapy.
"HyperDrive is real-time, interactive technology that will enable physicians to assess a large number of treatment options in only a few minutes. They will be able to evaluate the trade-offs between different strategies for maximizing dose to a tumor while reducing doses to nearby tissues and organs," Otto said. "Once physicians have used HyperDrive to find the optimal dose distribution for their patients, they will be able to generate an electronic treatment prescription that contains more information about the physician’s intent than was possible before."
"HyperDrive will be a powerful complement to the RapidPlan software, which uses prior knowledge to help clinical teams produce higher quality treatment plans," said Corey Zankowski, vice president, product and strategic portfolio management. "Combining HyperDrive with RapidPlan will let physicians create extremely refined 3-D prescriptions in minutes. This combination should result in better treatment plans with fewer back-and-forth consultations between the physician and the dosimetrist who creates the treatment plan based on the physician’s prescription."
Varian plans to integrate the HyperDrive technology into the company’s market-leading Eclipse treatment planning system, which is in use at some 3,400 cancer treatment centers around the world. It will be made available for sale in conjunction with Eclipse and RapidPlan. Eclipse was named "Category Leader" in the 2014 and 2013 "Best in KLAS: Software and Services Report" from KLAS, a research firm that specializes in monitoring and reporting on the performance of healthcare vendors.
The company acquired HyperDrive and other assets from Otto in September, and is not disclosing the financial details of the transaction.